INOVIO will publish data on the GBM trial of a combined treatment of DNA drugs with PD-1 inhibitors

On November 23, INOVIO announced that data from the DNA drug INO-5401 and INO-9012 in a new joint trial to treat newly diagnosed glioblastoma (GBM) in a joint trial with PD-1 inhibitor Libtayo® (Simipri monoma) will be published by Dr. David Reardon at the plenary meeting of the Society of Neuro-Oncology (SNO) 2020.
the study showed that INO-5401 plus INO-9012 with Libtayo, radiotherapy (RT) and TMZ were toned and immunogenic, and could improve median survival in newly diagnosed GBM patients.
18-month survival data show that 70 percent (14/20) of MGMT initiating son methylation GBM patients are still alive, while 50 percent (16/32) of the more difficult-to-treat MGMT starter non-methylation patients survive after 18 months.
total survival time was 17.9 months in patients with non-methylated GBM, which is favorable compared to historical controls;
interim data show that 19 (86%) of the 22 subjects in the MGMT initiator non-methylation queue have so far experienced IFN-γ T-cell reactions that exceed the baseline relative to one or more antigens encoded by INO-5401.
to date, 16 of the 17 subjects in the MGMT starter methylation queue (94%) have IFN-γ reactions that exceed the baseline relative to one or more antigens encoded by INO-5401.
The novel combination of ino-5401 and INO-9012 continues to exhibit good resistance safety not only with radiotherapy and TMZ, but also with Libtayo's PD-1 blocker developed by Regenerative and Sanofi.
will provide more data in the coming months, including relevant immunology and tissue data, as well as studies of total drug exposure and accompanying medications.
combinations of INO-5401, INO-9012 and Libtayo and these products have not yet been approved or evaluated by any regulatory body worldwide as to whether they can be used to treat new diagnostic GBMs.
note: There are deletions in the original text